Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus

Jing Huang, Rui gang Cai, Ping jun Meng, Ming juan Zhang, Chen xu Cui, Lin Yang, Da tong Chu, Yan Sun, Jin wan Wang

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

OBJECTIVE: Paclitaxel was used in a phase II trial in combination with cisplatin for esophageal cancer. The anti-tumor response, toxicity and survival of the treated patients were evaluated. METHODS: Thirty patients with advanced, unresectable, or complicated with metastasis were allotted, twenty-seven patients had no prior chemotherapy while 3 patients had received adjuvant chemotherapy. Patients were given paclitaxel 175 mg/m(2) by 3-hour infusion on D1, and cisplatin 40 mg/m(2) daily on D2 and D3. Granulocyte colony-stimulating factor (G-CSF) was not routinely administered unless the patient had neutropenia. Treatment was recycled every 21 days. RESULTS: Thirty patients (male/female, 28/2; median age 58) completed a median of 3 cycles and 27 patients were evaluable for response. Major objective responses were observed in 16 patients (59.3%; 95% confidence interval, 38.9% to 75.5%), including 5 complete responses (18.5%) and 11 partial responses (40.7%). The median time to tumor progression was 5.0 months (range, 1 to 23 months). The median actuarial survival was 9.7 months (range, 1 to 23 months). Twenty-eight patients were assessable for toxicity. The most common nonhematologic toxicity was alopecia. Grade 3 to 4 neutropenia was observed in 17.9% of the patients. Toxicity was manageable with dose attenuation and G-CSF support. CONCLUSION: The combination of paclitaxel and cisplatin can be considered as a main regimen in the treatment of advanced esophageal cancer.

Original languageEnglish
Pages (from-to)753-755
Number of pages3
JournalZhonghua zhong liu za zhi [Chinese journal of oncology]
Volume26
Issue number12
StatePublished - Dec 2004

Fingerprint

Dive into the research topics of 'Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus'. Together they form a unique fingerprint.

Cite this